Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating income | -$30.7M | -$93.0M | -$217M | -$286M |
| Net income | -$39.8M | -$84.0M | -$182M | -$256M |
| EPS (diluted) | -$16.16 | -$3.36 | -$3.30 | -$4.22 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$16.4M | -$74.8M | -$171M | -$227M |
| Capital expenditures | — | $167K | $1.15M | $5.15M |
| Free cash flow | — | -$74.9M | -$172M | -$233M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $152M | $118M | $142M | $132M |
| Total assets | $152M | $401M | $754M | $937M |
| Total liabilities | $9.98M | $21.5M | $37.2M | $33.3M |
| Retained earnings | -$39.8M | -$124M | -$306M | -$562M |
| Shares (wtd avg diluted) | 2.46M | 25.0M | 55.2M | 60.7M |
Every figure is extracted from Apogee Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.